MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- VENUS REMEDIES - NATCO PHARMA
VENUS REMEDIES vs NATCO PHARMA - Comparison Results
Current Valuations
| VENUS REMEDIES | NATCO PHARMA | VENUS REMEDIES/ NATCO PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | -13.9 | 34.8 | - | View Chart |
| P/BV | x | 0.9 | 4.9 | 18.7% | View Chart |
| Dividend Yield | % | 0.0 | 0.7 | - |
Financials
 VENUS REMEDIES  NATCO PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| VENUS REMEDIES Mar-18 |
NATCO PHARMA Mar-19 |
VENUS REMEDIES/ NATCO PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 126 | 849 | 14.8% | |
| Low | Rs | 61 | 557 | 11.0% | |
| Sales per share (Unadj.) | Rs | 301.8 | 573.8 | 52.6% | |
| Earnings per share (Unadj.) | Rs | -24.9 | 176.0 | -14.1% | |
| Cash flow per share (Unadj.) | Rs | 2.5 | 198.2 | 1.3% | |
| Dividends per share (Unadj.) | Rs | 0 | 6.25 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.9 | 0.0% | |
| Book value per share (Unadj.) | Rs | 293.3 | 842.7 | 34.8% | |
| Shares outstanding (eoy) | m | 12.34 | 36.50 | 33.8% | |
| Bonus/Rights/Conversions | - | BB | - | ||
| Price / Sales ratio | x | 0.3 | 1.2 | 25.3% | |
| Avg P/E ratio | x | -3.8 | 4.0 | -94.1% | |
| P/CF ratio (eoy) | x | 36.7 | 3.5 | 1,035.9% | |
| Price / Book Value ratio | x | 0.3 | 0.8 | 38.2% | |
| Dividend payout | % | 0 | 3.6 | 0.0% | |
| Avg Mkt Cap | Rs m | 1,154 | 25,660 | 4.5% | |
| No. of employees | `000 | 0.9 | 5.0 | 18.7% | |
| Total wages/salary | Rs m | 393 | 3,559 | 11.0% | |
| Avg. sales/employee | Rs Th | 4,026.1 | 4,225.3 | 95.3% | |
| Avg. wages/employee | Rs Th | 425.0 | 718.0 | 59.2% | |
| Avg. net profit/employee | Rs Th | -331.8 | 1,295.9 | -25.6% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 3,724 | 20,945 | 17.8% | |
| Other income | Rs m | 23 | 1,302 | 1.7% | |
| Total revenues | Rs m | 3,747 | 22,247 | 16.8% | |
| Gross profit | Rs m | 395 | 7,948 | 5.0% | |
| Depreciation | Rs m | 338 | 810 | 41.8% | |
| Interest | Rs m | 354 | 193 | 183.6% | |
| Profit before tax | Rs m | -275 | 8,247 | -3.3% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 32 | 1,823 | 1.7% | |
| Profit after tax | Rs m | -307 | 6,424 | -4.8% | |
| Gross profit margin | % | 10.6 | 37.9 | 27.9% | |
| Effective tax rate | % | -11.5 | 22.1 | -51.9% | |
| Net profit margin | % | -8.2 | 30.7 | -26.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 2,638 | 23,472 | 11.2% | |
| Current liabilities | Rs m | 2,305 | 7,287 | 31.6% | |
| Net working cap to sales | % | 8.9 | 77.3 | 11.6% | |
| Current ratio | x | 1.1 | 3.2 | 35.5% | |
| Inventory Days | Days | 135 | 92 | 146.9% | |
| Debtors Days | Days | 46 | 88 | 52.5% | |
| Net fixed assets | Rs m | 4,871 | 18,648 | 26.1% | |
| Share capital | Rs m | 123 | 365 | 33.8% | |
| "Free" reserves | Rs m | 3,496 | 34,525 | 10.1% | |
| Net worth | Rs m | 3,619 | 30,760 | 11.8% | |
| Long term debt | Rs m | 1,374 | 0 | - | |
| Total assets | Rs m | 7,509 | 43,031 | 17.4% | |
| Interest coverage | x | 0.2 | 43.7 | 0.5% | |
| Debt to equity ratio | x | 0.4 | 0 | - | |
| Sales to assets ratio | x | 0.5 | 0.5 | 101.9% | |
| Return on assets | % | 0.6 | 15.4 | 4.1% | |
| Return on equity | % | -8.5 | 20.9 | -40.6% | |
| Return on capital | % | 1.6 | 27.4 | 5.8% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 13.9 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | 517 | NA | - | |
| Fx inflow | Rs m | 0 | 11,536 | 0.0% | |
| Fx outflow | Rs m | 517 | 2,939 | 17.6% | |
| Net fx | Rs m | -517 | 8,597 | -6.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 514 | 6,688 | 7.7% | |
| From Investments | Rs m | -123 | -6,122 | 2.0% | |
| From Financial Activity | Rs m | -387 | -509 | 76.1% | |
| Net Cashflow | Rs m | 4 | 66 | 6.4% | |
Share Holding
| Indian Promoters | % | 32.9 | 52.0 | 63.1% | |
| Foreign collaborators | % | 0.0 | 1.5 | - | |
| Indian inst/Mut Fund | % | 0.2 | 7.8 | 2.3% | |
| FIIs | % | 0.6 | 16.6 | 3.5% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 66.4 | 26.0 | 255.4% | |
| Shareholders | 20,121 | 25,395 | 79.2% | ||
| Pledged promoter(s) holding | % | 36.4 | 0.0 | - |
Compare VENUS REMEDIES With: WYETH PIRAMAL ENTERPRISES JUBILANT PHARMOVA NEULAND LABS IPCA LABS
Compare VENUS REMEDIES With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
Related Views on News
NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)
Feb 17, 2020 | Updated on Feb 17, 2020For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)
Jun 12, 2019 | Updated on Jun 12, 2019For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)
May 28, 2019 | Updated on May 28, 2019For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)
Feb 17, 2020 | Updated on Feb 17, 2020For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games?(The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)
Apr 6, 2021Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
An India Revival Stock I'm Bullish On...(Profit Hunter)
Apr 9, 2021This could take India to the position of 3rd largest economy.
Why Did the Market Crash on Monday?(Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
Why the Market Fell Yesterday(Fast Profits Daily)
Apr 6, 2021In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
VENUS REMEDIES SHARE PRICE
Apr 16, 2021 03:36 PM
TRACK VENUS REMEDIES
- Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON VENUS REMEDIES
VENUS REMEDIES 8-QTR ANALYSIS
COMPARE VENUS REMEDIES WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.